Alternative splicing, epigenetic modifications and cancer: a dangerous triangle, or a hopeful one?. Gimeno-Valiente F, Lopez-Rodas G, Castillo J, Franco L. Cancers. 2022 Jan 22;14(3):560. doi: 10.3390/cancers14030560. PMID: 35158828

Automated whole-liver MRI segmentation to assess steatosis and iron quantification in chronic liver disease. Marti-Aguado D, Jimenez-Pastor A, Alberich-Bayarri A, Rodriguez-Ortega A, Alfaro-Cervello C, Mestre-Alagarda C, Bauza M, Gallen-Peris A, Valero-Perez E, Ballester MP, Gimeno-Torres M, Perez-Girbes A, Benlloch S, Perez-Rojas J, Puglia V, Ferrandez A, Aguilera V, Escudero-Garcia D, Serra MA, Marti-Bonmati L. Radiology. 2022 Feb;302(2):345-354. doi: 10.1148/radiol.2021211027. PMID: 34783592

Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy efficacy and clinical behavior of recurrences. Henriksen TV, Tarazona N, Frydendahl A, Reinert T, Gimeno-Valiente F, Carbonell-Asins JA, Sharma S, Renner D, Hafez D, Roda D, Huerta M, Rosello S, Madsen AH, Love US, Andersen PV, Thorlacius-Ussing O, Iversen LH, Gotschalck KA, Sethi H, Aleshin A, Cervantes A, Andersen CL. Clinical Cancer Research. 2022 Feb 1;28(3):507-517. doi: 10.1158/1078-0432.CCR-21-2404. PMID: 34625408

Clinical management of metastatic colorectal cancer in the era of precision medicine. Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. CA-A Cancer Journal for Clinicians. 2022 Jul;72(4):372-401. doi: 10.3322/caac.21728. PMID: 35472088

Colorectal cancer survival: prevalence of psychosocial distress and unmet supportive care needs. Andreu Y, Martinez P, Soto-Rubio A, Fernandez S, Bosch C, Cervantes A. Supportive Care in Cancer. 2022 Feb;30(2):1483-1491. doi: 10.1007/s00520-021-06513-1. PMID: 34529142

Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. Peters S, Pujol J, Dafni U, Domine M, Popat S, Reck M, Andrade J, Becker A, Moro-Sibilot D, Curioni-Fontecedro A, Molinier O, Nackaerts K, Insa Molla A, Gervais R, Lopez Vivanco G, Madelaine J, Mazieres J, Faehling M, Griesinger F, Majem M, Gonzalez Larriba J, Provencio Pulla M, Vervita K, Roschitzki-Voser H, Ruepp B, Mitchell P, Stahel R, Le Pechoux C, De Ruysscher D, ETOP/IFCT 4-12 STIMULI Collaborators. Annals of Oncology. 2022 Jan;33(1):67-79. doi: 10.1016/j.annonc.2021.09.011. PMID: 34562610

Corrigendum to «Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up»: [Annals of Oncology 29 suppl. 4 (2018) v238-iv255]. Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E; ESMO Guidelines Committee. Annals of Oncology. 2022 Jun;33(6):666. doi: 10.1016/j.annonc.2022.03.009. PMID: 35365377

Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. Kroese T, van Hillegersberg R, Schoppmann S, Deseyne P, Nafteux P, Obermannova R, Nordsmark M, Pfeiffer P, Hawkings M, Smyth E, Markar S, Hanna G, Cheong E, Chaudry A, Elme A, Adenis A, Piessen G, Gani C, Bruns C, Moehler M, Liakakos T, Reynolds J, Morganti A, Rosati R, Castoro C, D’Ugo D, Roviello F, Bencivenga M, de Manzoni G, Jeene P, van Sandick J, Muijs C, Slingerland M, Nieuwenhuijzen G, Wijnhoven B, Beerepoot L, Kolodziejczyk P, Polkowski W, Alsina M, Pera M, Kanonnikoff T, Nilsson M, Guckenberger M, Monig S, Wagner D, Wyrwicz L, Berbee M, Gockel I, Lordick F, Griffiths E, Verheij M, van Rossum P, van Laarhoven H, OMEC working group. European Journal of Cancer. 2022 Feb 5;164:18-29. doi: 10.1016/j.ejca.2021.11.032. PMID: 35134666

Efficacy of niraparib by time of surgery and postoperative residual disease status: a post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study. O’Cearbhaill R, Perez-Fidalgo J, Monk B, Tusquets I, McCormick C, Fuentes J, Moore R, Vulsteke C, Shahin M, Forget F, Bradley W, Hietanen S, O’Malley D, Dorum A, Slomovitz B, Baumann K, Selle F, Calvert P, Artioli G, Levy T, Kumar A, Malinowska I, Li Y, Gupta D, Gonzalez-Martin A. Gynecologic Oncology. 2022 Jul;166(1):36-43. doi: 10.1016/j.ygyno.2022.04.012. PMID: 35550709

ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe. Vaz-Luis I, Masiero M, Cavaletti G, Cervantes A, Chlebowski R, Curigliano G, Felip E, Ferreira A, Ganz P, Hegarty J, Jeon J, Johansen C, Joly F, Jordan K, Koczwara B, Lagergren P, Lambertini M, Lenihan D, Linardou H, Loprinzi C, Partridge A, Rauh S, Steindorf K, van der Graaf W, van de Poll-Franse L, Pentheroudakis G, Peters S, Pravettoni G. Annals of Oncology. 2022 Nov;33(11):1119-1133. doi: 10.1016/j.annonc.2022.07.1941. PMID: 35963481

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos-Arruda L, Diehn M, Italiano A, Lindberg J, Merker JD, Montagut C, Normanno N, Pantel K, Pentheroudakis G, Popat S, Reis-Filho JS, Tie J, Seoane J, Tarazona N, Yoshino T, Turner NC. Annals of Oncology. 2022 Aug;33(8):750-768. doi: 10.1016/j.annonc.2022.05.520. PMID: 35809752

Evaluation of antineoplastic delayed-type hypersensitivity skin reactions in vitro. Roger I, Montero P, Garcia A, Milara J, Ribera P, Perez-Fidalgo JA, Cortijo J. Pharmaceuticals. 2022 Sep 6;15(9):1111. doi: 10.3390/ph15091111. PMID: 36145332

First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. Italiano A, Cassier PA, Lin C, Alanko T, Peltola KJ, Gazzah A, Shiah HS, Calvo E, Cervantes A, Roda D, Tosi D, Gao B, Millward M, Warburton L, Tanner M, Englert S, Lambert S, Parikh A, Afar DE, Vosganian G, Moreno V. Cancer Immunology Immunotherapy. 2022 Feb;71(2):417-431. doi: 10.1007/s00262-021-02973-w. PMID: 34216247

First-in-human phase I Study of the OX40 agonist MOXR0916 in patients with advanced solid tumors. Kim T, Burris H, de Miguel Luken M, Pishvaian M, Bang Y, Gordon M, Awada A, Camidge D, Hodi F, McArthur G, Miller W, Cervantes A, Chow L, Lesokhin A, Rutten A, Sznol M, Rishipathak D, Chen S, Stefanich E, Pourmohamad T, Anderson M, Kim J, Huseni M, Rhee I, Siu L. Clinical Cancer Research. 2022 Aug 15;28(16):3452-3463. doi: 10.1158/1078-0432.CCR-21-4020. PMID: 35699599

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. Felip E, Moreno V, Morgensztern D, Curigliano G, Rutkowski P, Trigo JM, Calvo A, Kowalski D, Cortinovis D, Plummer R, Maio M, Ascierto PA, Vladimirov VI, Cervantes A, Zudaire E, Hazra A, T’jollyn H, Bandyopadhyay N, Greger JG, Attiyeh E, Xie H, Calvo E. Cancer Chemotherapy and Pharmacology. 2022 Apr;89(4):499-514. doi: 10.1007/s00280-022-04414-6. PMID: 35298698

Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, Vogel A, Smyth E. Annals of Oncology. 2022 Oct;33(10):1005-1020. doi: 10.1016/j.annonc.2022.07.004. PMID: 35914639

Impact of the COVID-19 pandemic on a cancer fast-track programme. Martinez M, Moragon S, Ortega-Morillo B, Monton-Bueno J, Simon S, Rosello S, Insa A, Viala A, Navarro J, Sanmartin A, Fluixa C, Julve A, Soriano D, Buch E, Pena A, Franco J, Martinez-Jabaloyas J, Marco J, Forner M, Cano A, Silvestre A, Teruel A, Bermejo B, Cervantes A, Chirivella Gonzalez I. Cancer Control. 2022 Jan-Dec;29:10732748221131000. doi: 10.1177/10732748221131000. PMID: 36355430

In the literature: April 2022. Ciardiello D, Roda D, Gambardella V, Cervantes A. ESMO Open. 2022 Apr 23;7(3):100479. doi: 10.1016/j.esmoop.2022.100479. PMID: 35472677

In the literature: December 2021. Montagut C, Gambardella V, Cabeza-Segura M, Fleitas T, Cervantes A. ESMO Open. 2022 Feb;7(1):100352. doi: 10.1016/j.esmoop.2021.100352. PMID: 34920292

In the literature: February 2022. Gambardella V, Cejalvo JM, Gonzalez Barrallo I, Gimeno Valiente F, Cervantes A. ESMO open. 2022 Feb 23;7(2):100411. doi: 10.1016/j.esmoop.2022.100411. PMID: 35219243

In the literature: July 2022. Gambardella V, Martinelli E, Tarazona N, Cervantes A. ESMO Open. 2022 Aug;7(4):100556. doi: 10.1016/j.esmoop.2022.100556. PMID: 35961192

In the literature: November 2022. Gambardella V, Cejalvo J, Cervantes A. ESMO Open. 2022 Nov 17;7(6):100643. doi: 10.1016/j.esmoop.2022.100643. PMID: 36403559

Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma. Cabeza-Segura M, Gambardella V, Gimeno-Valiente F, Carbonell-Asins JA, Alarcon-Molero L, Gonzalez-Vilanova A, Zuniga-Trejos S, Rentero-Garrido P, Villagrasa R, Gil M, Dura A, Richart P, Alonso N, Huerta M, Rosello S, Roda D, Tarazona N, Martinez-Ciarpaglini C, Castillo J, Cervantes A, Fleitas T. British Journal of Cancer. 2022 Dec;127(12):2198-2206. doi: 10.1038/s41416-022-02005-z. PMID: 36253523

Minimal residual disease in gastroesophageal adenocarcinoma: thesearch for the invisible. Tarazona N, Gimeno-Valiente F, Cervantes A. ESMO Open. 2022 Aug;7(4):100547. doi: 10.1016/j.esmoop.2022.100547. PMID: 35849878

MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer. Ferri C, Di Biase A, Bocchetti M, Zappavigna S, Wagner S, Le Vu P, Luce A, Cossu A, Vadakekolathu J, Miles A, Boocock D, Robinson A, Schwerdtfeger M, Tirino V, Papaccio F, Caraglia M, Regad T, Desiderio V. Journal of Experimental & Clinical Cancer Research. 2022 Jan 11;41(1):20. doi: 10.1186/s13046-021-02233-w. PMID: 35016717

Novel therapies for cardiometabolic disease: recent findings in studies with hormone peptide-derived G protein coupled receptor agonists. Jimenez-Marti E, Hurtado-Genoves G, Aguilar-Ballester M, Martinez-Hervas S, Gonzalez-Navarro H. Nutrients. 2022 Sep 13;14(18):3775. doi: 10.3390/nu14183775. PMID: 36145148

Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Obermannova R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, van Grieken N, Vogel A, Smyth E. Annals of Oncology. 2022 Oct;33(10):992-1004. doi: 10.1016/j.annonc.2022.07.003. PMID: 35914638

Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: is it cost-effective in Spain. Moya-Alarcon C, Gonzalez-Dominguez A, Ivanova-Markova Y, Gimeno-Ballester V, Barretina-Ginesta M, Perez-Fidalgo J, Redondo A. Gynecologic Oncology. 2022 Feb;164(2):406-414. doi: 10.1016/j.ygyno.2021.11.011. PMID: 34844775

Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial). Provencio M, Serna-Blasco R, Nadal E, Insa A, Garcia-Campelo MR, Casal Rubio J, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeno J, Cobo M, Lopez Vivanco G, Del Barco E, Bernabe Caro R, Vinolas N, Barneto Aranda I, Viteri S, Pereira E, Royuela A, Calvo V, Martin-Lopez J, Garcia-Garcia F, Casarrubios M, Franco F, Sanchez-Herrero E, Massuti B, Cruz-Bermudez A, Romero A. Journal of Clinical Oncology. 2022 Sep 1;40(25):2924-2933. doi: 10.1200/JCO.21.02660. PMID: 35576508

Paclitaxel induces epidermal molecular changes and produces subclinical alterations in the skin of gynecological cancer patients. Montero P, Perez-Leal M, Perez-Fidalgo JA, Sanz C, Estornut C, Roger I, Milara J, Cervantes A, Cortijo J. Cancers. 2022 Feb 23;14(5):1146. doi: 10.3390/cancers14051146. PMID: 35267454

Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas. Wermke M, Felip E, Gambardella V, Kuboki Y, Morgensztern D, Hamed Z, Liu M, Studeny M, Owonikoko T. Future Oncology. 2022 Aug;18(24):2639-2649. doi: 10.2217/fon-2022-0196. PMID: 35815644

Prognostic value of IGF2 mRNA-Binding Protein 3 (IGF2BP3) intratumoral expression in melanoma patients at the time of diagnosis: comparative analysis of rt-qpcr versus immunohistochemistry. Sanchez-Sendra B, Perez-Deben S, Gonzalez-Munoz JF, Murgui A, Monteagudo C. Cancers. 2022 May 7;14(9):2319. doi: 10.3390/cancers14092319. PMID: 35565448

Prospective real-world gynaecological cancer clinical registry with associated biospecimens: a collaborative model to promote translational research between GEICO and the Spanish Biobank Network. Lopez-Guerrero J, Mendiola M, Perez-Fidalgo J, Romero I, Torres A, Recalde D, Molina E, Gomez-Raposo C, Levin A, Herrero A, Alarcon J, Esteban C, Marquina G, Rubio M, Guerra E, Sanchez-Lorenzo L, Galvez-Montosa F, de Juan A, Churruca C, Gallego A, Gonzalez-Martin A. Cancers. 2022 Apr 13;14(8):1965. doi: 10.3390/cancers14081965. PMID: 35454870

Quality of life in cancer survivorship: Sociodemographic and disease-related moderators. Andreu Y, Martinez P, Soto-Rubio A, Perez-Marin M, Cervantes A, Arribas L. European Journal of Cancer Care. 2022 Nov;31(6):e13692. doi: 10.1111/ecc.13692. PMID: 36069249

RUNAT-BI: A Ruthenium(III) Complex as a Selective Anti-Tumor Drug Candidate against Highly Aggressive Cancer Cell Lines. Albanell-Fernandez M, Oltra S, Orts-Arroyo M, Ibarrola-Villava M, Carrasco F, Jimenez-Marti E, Cervantes A, Castro I, Martinez-Lillo J, Ribas G. Cancers. 2022 Dec 22;15(1):69. doi: 10.3390/cancers15010069. PMID: 36612065

Safety and efficacy of dostarlimab in patients with recurrent/advanced non-small cell lung cancer: results from cohort e of the Phase I GARNET Trial. Moreno V, Roda D, Pikiel J, Trigo J, Bosch-Barrera J, Drew Y, Kristeleit R, Hiret S, Bajor DL, Cruz P, Beck JT, Ghosh S, Dabrowski C, Antony G, Duan T, Veneris J, Zografos E, Subramanian J. Clinical Lung Cancer. 2022 Nov;23(7):e415-e427. doi: 10.1016/j.cllc.2022.05.013. PMID: 35729005

SARS-CoV-2 adaptive immunity in nursing home residents following a third dose of the Comirnaty COVID-19 vaccine. Gimenez E, Albert E, Zulaica J, Torres I, Rusu L, Rodriguez Moreno A, Burgos JS, Peiro S, Salas D, Vanaclocha H, Limon R, Alcaraz MJ, Sanchez-Paya J, Diez-Domingo J, Comas I, Gonzales Candelas F, Geller R, Navarro D. Clinical Infectious Diseases. 2022 Aug 24;75(1):e865-e868. doi: 10.1093/cid/ciac223. PMID: 35314856

SEOM-GEICO clinical guidelines on endometrial cancer (2021). Barretina Ginesta MP, Quindos M, Alarcon JD, Esteban C, Gaba L, Gomez C, Perez Fidalgo JA, Romero I, Santaballa A, Rubio Perez MJ. Clinical & Translational Oncology. 2022 Apr;24(4):625-634. doi: 10.1007/s12094-022-02799-7. PMID: 35312947

SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021) (vol 24, pg 646, 2022). Capdevila J, Gomez M, Guillot M, Paez D, Pericay C, Safont M, Tarazona N, Vera R, Vidal J, Sastre J. Clinical & Translational Oncology. 2022 Jul;24(7):1443-1444. doi: 10.1007/s12094-022-02855-2. PMID: 35596046

SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021). Capdevila J, Gomez MA, Guillot M, Paez D, Pericay C, Safont MJ, Tarazona N, Vera R, Vidal J, Sastre J. Clinical & Translational Oncology. 2022 Apr;24(4):646-657. doi: 10.1007/s12094-022-02816-9. PMID: 35303269

Short-term outcomes of colorectal cancer surgery in older patients: a novel nomogram predicting postoperative morbi-mortality. Moro-Valdezate D, Martin-Arevalo J, Ferro-Echevarria O, Pla-Marti V, Garcia-Botello S, Perez-Santiago L, Gadea-Mateo R, Tarazona N, Roda D, Rosello-Keranen S, Espi-Macias A. Langenbeck’s Archives of Surgery. 2022 Dec;407(8):3587-3597. doi: 10.1007/s00423-022-02688-1. PMID: 36129528

SMG8/SMG9 heterodimer loss modulates SMG1 kinase to drive ATR inhibitor resistance. Llorca-Cardenosa MJ, Aronson LI, Krastev DB, Nieminuszczy J, Alexander J, Song F, Dylewska M, Broderick R, Brough R, Zimmermann A, Zenke FT, Gurel B, Riisnaes R, Ferreira A, Roumeliotis T, Choudhary J, Pettitt SJ, de Bono J, Cervantes A, Haider S, Niedzwiedz W, Lord CJ, Chong IY. Cancer Research. 2022 Nov 2;82(21):3962-3973. doi: 10.1158/0008-5472.CAN-21-4339. PMID: 36273494

SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA. Prat A, Paz-Ares L, Juan M, Felip E, Garralda E, Gonzalez B, Arance A, Martin-Liberal J, Gavila J, Lopez-Gonzalez A, Miguel Cejalvo J, Izarzugaza Y, Amillano K, Garcia Corbacho J, Saura C, Racca F, Hierro C, Sanfeliu E, Gonzalez X, Canes J, Villacampa G, Salvador F, Pascual T, Mesia R, Cervantes A, Tabernero J. Future Oncology. 2022 Oct 6. doi: 10.2217/fon-2022-0660. PMID: 36200668

Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+breast tumors. Rivas EI, Linares J, Zwick M, Gomez-Llonin A, Guiu M, Labernadie A, Badia-Ramentol J, Llado A, Bardia L, Perez-Nunez I, Martinez-Ciarpaglini C, Tarazona N, Sallent-Aragay A, Garrido M, Celia-Terrassa T, Burgues O, Gomis RR, Albanell J, Calon A. Nature Communications. 2022 Sep 9;13(1):5310. doi: 10.1038/s41467-022-32782-3. PMID: 36085201

The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally. Van Schooten T, Derks S, Jimenez-Marti E, Carneiro F, Figueiredo C, Ruiz E, Alsina M, Molero C, Garrido M, Riquelme A, Caballero C, Lezcano E, O’Connor J, Esteso F, Farres J, Mas J, Lordick F, Vogt J, Cardone A, Girvalaki C, Cervantes A, Fleitas T. BMC Cancer. 2022 Jun 13;22(1):646. doi: 10.1186/s12885-022-09689-9. PMID: 35692051

The prognostic value of miR-125b, miR-200c and miR-205 in primary cutaneous malignant melanoma is independent of BRAF mutational status. Sanchez-Sendra B, Gonzalez-Munoz J, Perez-Deben S, Monteagudo C. Cancers. 2022 Mar 16;14(6):1532. doi: 10.3390/cancers14061532. PMID: 35326682

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy. Casarrubios M, Provencio M, Nadal E, Insa A, Garcia-Campelo MR, Lazaro-Quintela M, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeno J, Cobo M, Lopez Vivanco G, Del Barco E, Bernabe R, Vinolas N, Barneto Aranda I, Massuti B, Sierra-Rodero B, Martinez-Toledo C, Fernandez-Miranda I, Serna-Blanco R, Romero A, Calvo V, Cruz-Bermudez A. Journal for Immunotherapy of Cancer. 2022 Sep;10(9):e005320. doi: 10.1136/jitc-2022-005320. PMID: 36171009

Veliparib plus carboplatin and paclitaxel versus investigator’s choice of standard chemotherapy in patients with advanced non-squamous non-small cell lung cancer. Govindan R, Lind M, Insa A, Khan SA, Uskov D, Tafreshi A, Guclu S, Bar J, Kato T, Lee KH, Nakagawa K, Hansen O, Biesma B, Kundu MG, Dunbar M, He L, Ansell P, Sehgal V, Huang X, Glasgow J, Bach BA. Clinical Lung Cancer. 2022 May;23(3):214-225. doi: 10.1016/j.cllc.2022.01.005. PMID: 35331641

Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?. Insa A, Martin-Martorell P, Di Liello R, Fasano M, Martini G, Napolitano S, Vicidomini G, Cappabianca S, Franco R, Morgillo F, Della Corte CM. Critical Reviews in Oncology/Hematology. 2022 Jan;169:103538. doi: 10.1016/j.critrevonc.2021.103538. PMID: 34801700

Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. Huerta M, Rosello S, Sabater L, Ferrer A, Tarazona N, Roda D, Gambardella V, Alfaro-Cervello C, Garces-Albir M, Cervantes A, Ibarrola-Villava M. Cancers. 2021 Feb 27;13(5):994. doi: 10.3390/cancers13050994. PMID: 33673558

Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. Sierra-Rodero B, Cruz-Bermudez A, Nadal E, Garitaonaindia Y, Insa A, Mosquera J, Casal-Rubio J, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeno J, Cobo M, Lopez Vivanco G, Del Barco E, Bernabe Caro R, Vinolas N, Barneto Aranda I, Viteri S, Massuti B, Laza-Briviesca R, Casarrubios M, Garcia-Grande A, Romero A, Franco F, Provencio M. Journal for ImmunoTherapy of Cancer. 2021 Aug;9(8):e002804. doi: 10.1136/jitc-2021-002804. PMID: 34446577

Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants. Lambertini M, Ceppi M, Hamy A, Caron O, Poorvu P, Carrasco E, Grinshpun A, Punie K, Rousset-Jablonski C, Ferrari A, Paluch-Shimon S, Toss A, Senechal C, Puglisi F, Pogoda K, Perez-Fidalgo J, De Marchis L, Ponzone R, Livraghi L, Estevez-Diz M, Villarreal-Garza C, Dieci M, Clatot F, Duhoux F, Graffeo R, Teixeira L, Cordoba O, Sonnenblick A, Ferreira A, Partridge A, Di Meglio A, Saule C, Peccatori F, Bruzzone M, t’Kint de Roodenbeke M, Ameye L, Balmana J, Del Mastro L, Azim H. NPJ breast cancer. 2021 Feb 12;7(1):16. doi: 10.1038/s41523-021-00224-w. PMID: 33579978

Clinical Case Presentation and Discussion During ESO-ESMO Masterclass: a 10-Year Interactive Educational Experience. Pavlidis N, Peccatori F, Aapro M, Cervantes Ruiperez A, Stahel R, Eniu A, Cavalli F, Costa A. Journal of Cancer Education. 2021 Oct;36(5):1124-1128. doi: 10.1007/s13187-020-01744-y. PMID: 32303982

Clinicians’ attitude to doublet plus Anti-EGFR versus triplet plus bevacizumab as first-line treatment in left-sided RAS and BRAF wild-type metastatic colorectal cancer patients: a multicenter, «real-life», case-control study. Parisi A, Porzio G, Cannita K, Venditti O, Avallone A, Filippi R, Salvatore L, Tortora G, Ribelli M, Nigro O, Gelsomino F, Spallanzani A, Zurlo V, Leo S, Dell’Aquila E, Claudia F, Lombardi P, Keranen S, Aimar G, Depetris I, Giampieri R, Morelli C, De Tursi M, Tinari N, Di Pietro F, De Galitiis F, Zanaletti N, Troiani T, Vitale P, Garajova I, Ghidini M, Spinelli G, Zoratto F, Roberto M, Ierino D, Petrillo A, D’Orazio C, Ficorella C, Cortellini A. Clinical Colorectal Cancer. 2021 Dec;20(4):318-325. doi: 10.1016/j.clcc.2021.07.003. PMID: 34380594

Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial. Romero A, Jantus-Lewintre E, Garcia-Pelaez B, Royuela A, Insa A, Cruz P, Collazo A, Altozano J, Vidal O, Diz P, Cobo M, Hernandez B, Estevez S, Benitez G, Guirado M, Majem M, Bernabe R, Ortega A, Blasco A, Bosch-Barrera J, Jurado J, Gonzalez J, Viteri S, Giron C, Massuti B, Martin A, Rodriguez-Festa A, Calabuig-Farinas S, Molina-Vila M, Provencio M. Molecular Oncology. 2021 Jan;15(1):43-56. doi: 10.1002/1878-0261.12832. PMID: 33107189

Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Gambardella V, Martinez-Ciarpaglini C, Fleitas T, Cervantes A. ESMO Open. 2021 Nov 6;6(6):100285. doi: 10.1016/j.esmoop.2021.100285. PMID: 34752996

Cutaneous lymphadenoma is a distinct trichoblastoma-like lymphoepithelial tumor with diffuse androgen receptor immunoreactivity, notch1 ligand in reed-sternberg-like cells, and common EGFR somatic mutations. Monteagudo C, Funez R, Sanchez-Sendra B, Gonzalez-Munoz JF, Nieto G, Alfaro-Cervello C, Murgui A, Barr R. The American Journal of Surgical Pathology. 2021 Oct 1;45(10):1382-1390. doi: 10.1097/PAS.0000000000001727. PMID: 34232601

Digital pathology: accurate technique for quantitative assessment of histological features in metabolic-associated fatty liver disease. Marti-Aguado D, Rodriguez-Ortega A, Mestre-Alagarda C, Bauza M, Valero-Perez E, Alfaro-Cervello C, Benlloch S, Perez-Rojas J, Ferrandez A, Alemany-Monraval P, Escudero-Garcia D, Monton C, Aguilera V, Alberich-Bayarri A, Serra M, Marti-Bonmati L. Alimentary Pharmacology & Therapeutics. 2021 Jan;53(1):160-171. doi: 10.1111/apt.16100. PMID: 32981113

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer. Kaminska K, Akrap N, Staaf J, Alves C, Ehinger A, Ebbesson A, Hedenfalk I, Beumers L, Veerla S, Harbst K, Ehmsen S, Borgquist S, Borg A, Perez-Fidalgo A, Ditzel H, Bosch A, Honeth G. Breast Cancer Research. 2021 Feb 18;23(1):26. doi: 10.1186/s13058-021-01402-1. PMID: 33602273

Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma. Riudavets M, Bosch-Barrera J, Cabezon-Gutierrez L, Tain P, Hernandez A, Alonso M, Blanco R, Galvez E, Insa A, Mielgo X, Moran T, Ponce S, Roa D, Sanchez J, Majem M. Clinical & Translational Oncology. 2021 Dec;23(12):2560-2567. doi: 10.1007/s12094-021-02661-2. PMID: 34292495

Epigenetic Mechanisms Are Involved in the Oncogenic Properties of ZNF518B in Colorectal Cancer. Gimeno-Valiente F, Riffo-Campos A, Torres L, Tarazona N, Gambardella V, Cervantes A, Lopez-Rodas G, Franco L, Castillo J. Cancers. 2021 Mar 21;13(6):1433. doi: 10.3390/cancers13061433. PMID: 33801071

ESMO pays tribute to Professor Jose Baselga. Peters S, Tabernero J, Cervantes A, Banerjee S, Giuliani R, Lordick F. Annals of Oncology. 2021 Jul;32(7):823-824. doi: 10.1016/j.annonc.2021.04.001. PMID: 34090547

ESMO pays tribute to Professor Jose Baselga. Peters S, Tabernero J, Cervantes A, Banerjee S, Giuliani R, Lordick F. ESMO open. 2021 Jul;32(7):823-824. doi: 10.1016/j.annonc.2021.04.001. PMID: 34144776

ESO-ESMO Masterclass in Clinical Oncology: Analysis and Evaluation of the Learning Self-Assessment Test. Pavlidis N, Peccatori F, Aapro M, Eniu A, Stahel R, Cervantes A, Cavalli F, Costa A. Journal of Cancer Education. 2021 Jun;36(3):556-560. doi: 10.1007/s13187-019-01664-6. PMID: 31845109

First-in-human phase I study of a next-generation, oral, transforming growth factor-beta receptor 1 inhibitor, LY3200882 in patients with advanced cancer. Yap TA, Vieito M, Baldini C, Sepulveda-Sanchez JM, Kondo S, Simonelli M, Cosman R, van der Westhuizen A, Atkinson V, Carpentier AF, Lohr M, Redman R, Mason W, Cervantes A, Le Rhun E, Ochsenreither S, Warren L, Zhao Y, Callies S, Estrem ST, Man M, Gandhi L, Avsar E, Melisi D. Clinical Cancer Research. 2021 Dec 15;27(24):6666-6676. doi: 10.1158/1078-0432.CCR-21-1504. PMID: 34548321

First-line biological agents plus chemotherapy in older patients with metastatic colorectal cancer: a retrospective pooled analysis. Garcia-Alfonso P, Diaz-Rubio E, Abad A, Carrato A, Massuti B, Ortiz-Morales M, Mozo J, Munoz A, Duran G, Sastre J, Safont M, Ferreiro R, Rivera F, Gonzalez E, Valladares-Ayerbes M, Gravalos C, Alonso-Orduna V, Vieitez J, Yubero A, Aranda E, Spanish Cooperative Grp Treatment. Drugs & Aging. 2021 Mar;38(3):219-231. doi: 10.1007/s40266-021-00834-w. PMID: 33615402

Folliculotropic mycosis fungoides with flexural eruptive cysts and comedones in a 14-year-old boy. Roca-Gines J, Alfaro-Cervello C, Sanchez-Arraez J, Torres-Navarro I, Navarro-Mira MA, Monteagudo C, Botella-Estrada R. American Journal of Dermatopathology. 2021 Sep 1;43(9):656-658. doi: 10.1097/DAD.0000000000001958. PMID: 33989213

Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. Bertocchi A, Carloni S, Ravenda PS, Bertalot G, Spadoni I, Lo Cascio A, Gandini S, Lizier M, Braga D, Asnicar F, Segata N, Klaver C, Brescia P, Rossi E, Anselmo A, Guglietta S, Maroli A, Spaggiari P, Tarazona N, Cervantes A, Marsoni S, Lazzari L, Jodice M, Giovanna L, Chiara E, Marco PS, Di Fiore PP, Viale G, Spinelli A, Pozzi C, Penna G, Rescigno M. Cancer Cell. 2021 May 10;39(5):708-724.e11. doi: 10.1016/j.ccell.2021.03.004. PMID: 33798472

Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM). Jimenez-Labaig P, Pacheco-Barcia V, Cebria A, Galvez F, Obispo B, Paez D, Quilez A, Quintanar T, Ramchandani A, Remon J, Rogado J, Sanchez D, Sanchez-Canovas M, Sanz-Garcia E, Sesma A, Tarazona N, Cotes A, Gonzalez E, Bosch-Barrera J, Fernandez A, Felip E, Vera R, Rodriguez-Lescure A, Elez E. ESMO Open. 2021 Jul 26;6(4):100215. doi: 10.1016/j.esmoop.2021.100215. PMID: 34325108

In the literature: April 2021. Martin-Martorell P, Gonzalez-Barrallo I, Gambardella V, Cejalvo J M, Cervantes A. ESMO open. 2021 Apr 19;6(3):100116. doi: 10.1016/j.esmoop.2021.100116. PMID: 33887688

In the literature: August 2021. Gambardella V, Alfaro-Cervello C, Cejalvo J, Tapia M, Cervantes A. ESMO Open. 2021 Aug 16;6(5):100247. doi: 10.1016/j.esmoop.2021.100247. PMID: 34411970

In the literature: December 2020. Gambardella V, Ibarrola-Villaba M, Tarazona N, Cervantes A. ESMO Open. 2021 Jan 4;6(1):100009. doi: 10.1016/j.esmoop.2020.100009. PMID: 33399075

In the literature: February 2021. Cejalvo J, Gambardella V, Fleitas T, Cervantes A. ESMO Open. 2021 Feb 24;6(2):100061. doi: 10.1016/j.esmoop.2021.100061. PMID: 33639602

In the literature: June 2021. Gambardella V, Candia L, Tapia M, Cejalvo JM, Cervantes A. ESMO open. 2021 Jun;6(3):100186. doi: 10.1016/j.esmoop.2021.100186. PMID: 34098228

LungBEAM: a prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. Garrido P, Paz-Ares L, Majem M, Moran T, Trigo JM, Bosch-Barrera J, Garcia-Campelo R, Gonzalez-Larriba JL, Sanchez-Torres JMiguel, Isla D, Vinolas N, Camps C, Insa A, Juan O, Massuti B, Paredes A, Artal A, Lopez-Brea M, Palacios J, Felip E. Cancer Medicine. 2021 Sep;10(17):5878-5888. doi: 10.1002/cam4.4135.PMID: 34296539

Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. Gambardella V, Lombardi P, Carbonell-Asins JA, Tarazona N, Cejalvo JM, Gonzalez-Barrallo I, Martin-Arana J, Tebar-Martinez R, Viala A, Bruixola G, Hernando C, Blasco I, Papaccio F, Martinez-Ciarpaglini C, Alfaro-Cervello C, Seda-Garcia E, Blesa S, Chirivella I, Castillo J, Monton-Bueno JV, Rosello S, Huerta M, Perez-Fidalgo A, Martin-Martorell P, Insa-Molla A, Fleitas T, Rentero-Garrido P, Zuniga-Trejos S, Cervantes A, Roda D. British Journal of Cancer. 2021 Oct;125(9):1261-1269. doi: 10.1038/s41416-021-01502-x. PMID: 34493820

Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phaseII trial (ROLANDO study). Perez-Fidalgo J, Cortes A, Guerra E, Garcia Y, Iglesias M, Bohn Sarmiento U, Calvo Garcia E, Manso Sanchez L, Santaballa A, Oaknin A, Redondo A, Rubio M, Gonzalez-Martin A. ESMO Open. 2021 Jul 27;6(4):100212. doi: 10.1016/j.esmoop.2021.100212. PMID: 34329939

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. Yoshino T, Argiles G, Oki E, Martinelli E, Taniguchi H, Arnold D, Mishima S, Li Y, Smruti B, Ahn J, Faud I, Chee C, Yeh K, Lin P, Chua C, Hasbullah H, Lee M, Sharma A, Sun Y, Curigliano G, Bando H, Lordick F, Yamanaka T, Tabernero J, Baba E, Cervantes A, Ohtsu A, Peters S, Ishioka C, Pentheroudakis G. Annals of Oncology. 2021 Dec;32(12):1496-1510. doi: 10.1016/j.annonc.2021.08.1752. PMID: 34411693

Peritoneal invasion and metachronous peritoneal metastases after colon cancer surgery: The role of homogeneous, reliable assessment and confounders. Pellino G, Garcia-Granero E, Cervantes A. European Journal of Surgical Oncology. 2021 Oct;47(10):2697. doi: 10.1016/j.ejso.2021.06.031. PMID: 34217579

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers. Jhaveri K, Chang M, Juric D, Saura C, Gambardella V, Melnyk A, Patel M, Ribrag V, Ma C, Aljumaily R, Bedard P, Sachdev J, Dunn L, Won H, Bond J, Jones S, Savage H, Scaltriti M, Wilson T, Wei M, Hyman D. Clinical Cancer Research. 2021 Jan 15;27(2):447-459. doi: 10.1158/1078-0432.CCR-20-2657. PMID: 33148674

Post-induction management in patients with left-sided RAS and BRAF wild-type metastatic colorectal cancer treated with first-line anti-egfr-based doublet regimens: a multicentre study. Parisi A, Cortellini A, Venditti O, Filippi R, Salvatore L, Tortora G, Ghidini M, Nigro O, Gelsomino F, Zurlo IV, Fulgenzi C, Lombardi P, Roselló Keränen S, Depetris I, Giampieri R, Morelli C, Di Marino P, Di Pietro FR, Zanaletti N, Vitale P, Garajova I, Spinelli GP, Zoratto F, Roberto M, Petrillo A, Aimar G, Patruno L, D’Orazio C, Ficorella C, Ferri C, Porzio G. Frontiers in Oncology. 2021 Oct 27;11:712053. doi: 10.3389/fonc.2021.712053. PMID: 34778029

Postoperative ctDNA monitoring: a canary in a coalmine. Lumish M, Tarazona N, Janjigian Y. Annals of oncology. 2021 Apr;32(4):431-433. doi: 10.1016/j.annonc.2021.01.005. PMID: 33484835

Potential biomarkers associated with multiple sclerosis pathology. Mathur D, Mishra BK, Rout S, Lopez-Iranzo FJ, Lopez-Rodas G, Vallamkondu J, Kandimalla R, Casanova B. International Journal of Molecular Sciences. 2021 Sep 25;22(19):10323. doi: 10.3390/ijms221910323. PMID: 34638664

Pre-treatment tissue TCR repertoire evenness is associated with complete pathological response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy. Casarrubios M, Cruz-Bermudez A, Nadal E, Insa A, Garcia-Campelo R, Lazaro M, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, de Castro-Carpeno J, Cobo M, Lopez-Vivanco G, Del Barco E, Bernabe Caro R, Vinolas N, Barneto Aranda I, Viteri S, Massuti B, Barquin M, Laza-Briviesca R, Sierra-Rodero B, Parra E, Sanchez-Espiridion B, Rocha P, Kadara H, Wistuba I, Romero A, Calvo V, Provencio M. Clinical Cancer Research. 2021 Nov 1;27(21):5878-5890. doi: 10.1158/1078-0432.CCR-21-1200. PMID: 34376534

Prognostic implications of surgical specimen quality on the oncological outcomes of open and laparoscopic surgery in mid and low rectal cancer. Pla-Marti V, Martin-Arevalo J, Moro-Valdezate D, Garcia-Botello S, Perez-Santiago L, Lapena-Rodriguez M, Bauza-Collado M, Huerta M, Rosello-Keranen S, Espi-Macias A. Langenbeck’s archives of surgery. 2021 Dec;406(8):2759-2767. doi: 10.1007/s00423-021-02351-1. PMID: 34716825

Radiomics and radiogenomics in head and neck squamous cell carcinoma: potential contribution to patient management and challenges. Bruixola G, Remacha E, Jimenez-Pastor A, Dualde D, Viala A, Monton J, Ibarrola-Villava M, Alberich-Bayarri A, Cervantes A. Cancer Treatment Reviews. 2021 Sep;99:102263. doi: 10.1016/j.ctrv.2021.102263. PMID: 34343892

Reply to the letter to the editor: adjuvant nivolumab for the management of the pathological residual disease in esophageal or junctional tumors: a word of caution by P.K. Garg, R. Kumar and P. Dixit. Smyth EC, Gambardella V, Cervantes A, Fleitas T. Annals of Oncology. 2021 Sep;32(9):1190-1191. doi: 10.1016/j.annonc.2021.05.795. PMID: 34033882

Retrospective study of regorafenib versus TAS-102 efficacy and safety in chemorefractory Metastatic Colorectal Cancer (mCRC) patients: a multi-institution real life clinical data. Vitale P, Zanaletti N, Famiglietti V, De Falco V, Cervantes A, Rosellò S, Fenocchio E, Milanesio M, Lombardi P, Ciardiello D, Martini G, Martinelli E, Ciardiello F, Troiani T, Napolitano S. Clinical Colorectal Cancer. 2021 Sep;20(3):227-235. doi: 10.1016/j.clcc.2021.06.002. PMID: 34226142

Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer. Condorelli M, Bruzzone M, Ceppi M, Ferrari A, Grinshpun A, Hamy AS, de Azambuja E, Carrasco E, Peccatori FA, Di Meglio A, Paluch-Shimon S, Poorvu PD, Venturelli M, Rousset-Jablonski C, Senechal C, Livraghi L, Ponzone R, De Marchis L, Pogoda K, Sonnenblick A, Villarreal-Garza C, Cordoba O, Teixeira L, Clatot F, Punie K, Graffeo R, Dieci MV, Perez-Fidalgo JA, Duhoux FP, Puglisi F, Ferreira AR, Blondeaux E, Peretz-Yablonski T, Caron O, Saule C, Ameye L, Balmana J, Partridge AH, Azim HA, Demeestere I, Lambertini M. ESMO Open. 2021 Nov 11;6(6):100300. doi: 10.1016/j.esmoop.2021.100300. PMID: 34775302

SEOM clinical guideline in ovarian cancer (2020). Redondo A, Guerra E, Manso L, Martin-Lorente C, Martinez-Garcia J, Perez-Fidalgo J, Varela M, Rubio M, Barretina-Ginesta M, Gonzalez-Martin A. Clinical & translational oncology. 2021 May;23(5):961-968. doi: 10.1007/s12094-020-02545-x. PMID: 33515422

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Bahadoer R, Dijkstra E, van Etten B, Marijnen C, Putter H, Kranenbarg E, Roodvoets A, Nagtegaal I, Beets-Tan R, Blomqvist L, Fokstuen T, Ten Tije A, Capdevila J, Hendriks M, Edhemovic I, Cervantes A, Nilsson P, Glimelius B, van de Velde C, Hospers G, RAPIDO collaborative investigators. Lancet. Oncology. 2021 Jan;22(1):29-42. doi: 10.1016/S1470-2045(20)30555-6. PMID: 33301740

Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib. Malhi V, Budha N, Sane R, Huang J, Liederer B, Meng R, Patel P, Deng Y, Cervantes A, Tabernero J, Musib L. Cancer Chemotherapy and Pharmacology. 2021 Dec;88(6):921-930. doi: 10.1007/s00280-021-04344-9. PMID: 34471960

Ten-year assessment of a cancer fast-track programme to connect primary care with oncology: reducing time from initial symptoms to diagnosis and treatment initiation. Martinez MT, Monton-Bueno J, Simon S, Ortega B, Moragon S, Rosello S, Insa A, Navarro J, Sanmartin A, Julve A, Buch E, Pena A, Franco J, Martinez-Jabaloyas J, Marco J, Forner MJ, Cano A, Silvestre A, Teruel A, Lluch A, Cervantes A, Chirivella Gonzalez I. ESMO open. 2021 May 11;6(3):100148. doi: 10.1016/j.esmoop.2021.100148. PMID: 33989988

The COVID-19 pandemic could be a setback for gender equality in oncology-and a key moment to push ahead with transformative policies. Cervantes A. ESMO Open. 2021 Jun;6(3):100169. doi: 10.1016/j.esmoop.2021.100169. PMID: 34144777

Trends and outcome of neoadjuvant treatment for rectal cancer: A retrospective analysis and critical assessment of a 10-year prospective national registry on behalf of the Spanish Rectal Cancer Project. Pellino G, Alós R, Biondo S, Codina-Cazador A, Enríquez-Navascues J, Espín-Basany E, Roig-Vila J, Cervantes Ruiperez A, Carceller R, Spanish Rectal Cancer Project collaborators. EJSO. 2021 Feb;47(2):276-284. doi: 10.1016/j.ejso.2020.04.056. PMID: 32950316

Unexpected finding of iIntravascular large B-cell lymphoma by a skin biopsy. Guillen-Climent S, Garcia-Vazquez A, Martinez-Ciarpaglini C. Medicina Clinica. 2021 Aug 13;157(3):151-152. doi: 10.1016/j.medcli.2020.04.051. PMID: 32951879

Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Vogel A, Martinelli E, ESMO Guidelines Commite. Annals of Oncology. 2021 Jun;32(6):801-805. doi: 10.1016/j.annonc.2021.02.014. PMID: 33716105

Using DNA sequencing data to quantify T cell fraction and therapy response. Bentham R, Litchfield K, Watkins T, Lim E, Rosenthal R, Martinez-Ruiz C, Hiley C, Al Bakir M, Salgado R, Moore D, Jamal-Hanjani M, Swanton C, McGranahan N, TRACERx Consortium. Nature. 2021 Sep;597(7877):555-560. doi: 10.1038/s41586-021-03894-5. PMID: 34497419

Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer A Secondary Analysis of the AVANT Trial. Chibaudel B, Henriques J, Rakez M, Brenner B, Kim Tae Won, Martinez Villacampa M, Gallego Plazas J, Cervantes A, Shim K, Jonker D, Guerin Meyer V, Mineur L, Banzi C, Dewdney A, Dejthevaporn T, Bloemendal HJ, Roth A, Moehler M, Aranda E, Van Cutsem E, Tabernero J, Schmoll HJ, Hoff PM, Andre T, de Gramont A. Jama Network Open. 2020 Oct 1;3(10):e2020425. doi: 10.1001/jamanetworkopen.2020.20425. PMID: 33074326

Aurora kinases in ovarian cancer. Perez Fidalgo J, Gambardella V, Pineda Merlo B, Burgues Gasion O, Piñero Sanchez O, Cervantes Ruiperez A. ESMO Open. 2020 Oct;5(5):e000718. doi: 10.1136/esmoopen-2020-000718. PMID: 33087400

Changing the education paradigm in oncology: ESO masterclass, 17 years of continuous success. Pavlidis N, Peccatori F, Aapro M, Rolfo C, Cervantes Ruiperez A, Stahel R, Eniu A, Cavalli F, Costa A. Critical Reviews in Oncology Hematology. 2020 Feb;146:102798. doi: 10.1016/j.critrevonc.2019.07.022. PMID: 31918958

Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas. Derks S, de Klerk L, Xu X, Fleitas Kanonnikoff T, Liu K, Liu Y, Dietlein F, Margolis C, Chiaravalli A, Da Silva A, Ogino S, Akarca F, Freeman G, Rodig S, Hornick J, VAN Allen E, Li B, Liu S, Thorsson V, Bass A. Annals of Oncology. 2020 Aug;31(8):1011-1020. doi: 10.1016/j.annonc.2020.04.011. PMID: 32387455

Chronological Age Interacts with the Circadian Melatonin Receptor 1B Gene Variation, Determining Fasting Glucose Concentrations in Mediterranean Populations. Additional Analyses on Type-2 Diabetes Risk. Sorli J, Barragan R, Coltell O, Portoles O, Pascual E, Ortega-Azorin C, Gonzalez J, Estruch R, Saiz C, Perez-Fidalgo A, Ordovas J, Corella D. Nutrients. 2020 Oct 29;12(11):3323. doi: 10.3390/nu12113323. PMID: 33138317

Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL). Garcia Campelo R, Arrieta O, Massuti B, Rodriguez Abreu D, Ortega Granados AL, Majem M, Vicente D, Lianes P, Bosch Barrera J, Insa A, Domine M, Reguart N, Guirado M, Sala MA, Vazquez Estevez S, Bernabe Caro, R, Drozdowskyj A, Verdu A, Karachaliou N, Molina Vila MA, Rosell R. Lung Cancer. 2020 Dec;150:62-69. doi: 10.1016/j.lungcan.2020.09.018. PMID: 33070053

Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer – Results of the international randomized RAPIDO-trial (vol 147, pg 75, 2020). van der Valk MJM, Marijnen CAM, van Etten B, Dijkstra EA, Hilling DE, Kranenbarg EM, Putter H, Roodvoets AGH, Bahadoer RR, Fokstuen T, ten Tije AJ, Capdevila J, Hendriks MP, Edhemovic I, Cervantes A, de Groot Derk JA, Nilsson PJ, Glimelius B, van de Velde CJH, Hospers GAP. Radiotherapy and Oncology. 2020 Jun;147:e1. doi: 10.1016/j.radonc.2020.06.006. PMID: 32564889

Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer – Results of the international randomized RAPIDO-trial. van der Valk MJM, Marijnen CAM, van Etten B, Dijkstra EA, Hilling DE, Kranenbarg EM, Putter H, Roodvoets AGH, Bahadoer RR, Fokstuen T, ten Tije AJ, Capdevila J, Hendriks MP, Edhemovic I, Cervantes A, de Groot DJA, Nilsson PJ, Glimelius B, van de Velde CJH, Hospers GAP. Radiotherapy and Oncology. 2020 Jun;147:75-83. doi: 10.1016/j.radonc.2020.03.011. PMID: 32240909

Computational evaluation and in vitro validation of new Epidermal Growth Factor Receptor inhibitors. Gomez-Ganau S, Castillo Aliaga J, Cervantes Ruiperez A, de Julian Ortiz J, Gozalbes R. Current Topics in Medicinal Chemistry. 2020;20(18):1628-1639. doi: 10.2174/1568026620666200603122726. PMID: 32493189

Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer. Tarazona Llavero N, Gimeno Valiente F, Gambardella V, Huerta Alvaro M, Roselló Keränen S, Zúñiga Trejos S, Calon A, Carbonell Asins J, Fontana E, Martínez Ciarpaglini M, Eason K, Rentero Garrido P, Fleitas Kanonnikoff T, Papaccio F, Moro Valdezate D, Nyamundanda G, Castillo Aliaga J, Espí Macias A, Sadanandam A, Roda Perez D, Cervantes Ruiperez A. ESMO Open. 2020 Sep;5(5):e000847. doi: 10.1136/esmoopen-2020-000847. PMID: 32967918

Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study. Velasco R, Mercadal S, Vidal N, Alana M, Barcelo M, Ibanez-Julia M, Bobillo S, Caldu Agud R, Garcia Molina E, Martinez P, Cacabelos P, Muntanola A, Garcia-Catalan G, Sancho J, Camro I, Lado T, Erro M, Gomez-Vicente L, Salar A, Caballero A, Sole-Rodriguez M, Gallego Perez-Larraya J, Huertas N, Estela J, Baron M, Barbero-Bordallo N, Encuentra M, Dlouhy I, Bruna J, Graus F, Bruixola Campos G, GELTAMO & GENOSEN Grp. Journal of Neuro-Oncology. 2020 Jul;148(3):545-554. doi: 10.1007/s11060-020-03547-z. PMID: 32524392

Easy One-Step Amplification and Labeling Procedure for Copy Number Variation Detection. Blesa Luján S, Olivares Gazquez M, Alic A, Serrano Alcalá A, Lendinez Tortajada V, Gonzalez Albert V, Olivares Ordoñez L, Martinez Hervas S, Juanes Tébar J, Marin P, Real Collado J, Navarro Cubells B, García García A, Chaves Martínez F, Ivorra C. Clinical Chemistry. 2020 Mar 1;66(3):463-473. doi: 10.1093/clinchem/hvaa002. PMID: 32068788

Editorial debate: Challenges we oncologists, working within a universal healthcare system, have to face in these hard times. Cervantes Ruiperez A. ESMO Open. 2020 May;5(3):e000800. doi: 10.1136/esmoopen-2020-000800. PMID: 32366509

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. Smyth L, Piha-Paul S, Won H, Schram A, Saura C, Loi S, Lu J, Shapiro G, Juric D, Mayer I, Arteaga C, de la Fuente M, Brufksy A, Spanggaard I, Mau-Sorensen M, Arnedos M, Moreno V, Boni V, Sohn J, Schwartzberg L, Gonzalez-Farre X, Cervantes Ruiperez A, Bidard F, Gorelick A, Lanman R, Nagy R, Ulaner G, Chandarlapaty S, Jhaveri K, Gavrila E, Zimel C, Selcuklu S, Melcer M, Samoila A, Cai Y, Scaltriti M, Mann G, Xu F, Eli L, Dujka M, Lalani A, Bryce R, Baselga J, Taylor B, Solit D, Meric-Bernstam F, Hyman D. Cancer Discovery. 2020 Feb;10(2):198-213. doi: 10.1158/2159-8290.CD-19-0966. PMID: 31806627

Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets-a narrative review. Samartzis E, Labidi-Galy S, Moschetta M, Uccello M, Kalaitzopoulos D, Perez-Fidalgo J, Boussios S. Annals of Translational Medicine. 2020 Dec;8(24):1712. doi: 10.21037/atm-20-3022a. PMID: 33490224

EPDR1 up-regulation in human colorectal cancer is related to staging and favours cell proliferation and invasiveness. Gimeno Valiente F, Riffo Campos Á, Ayala Gallego G, Tarazona Llavero N, Gambardella V, Rodriguez F, Huerta Alvaro M, Martínez Ciarpaglini M, Monton Bueno J, Roselló Keränen S, Roda Perez D, Cervantes Ruiperez A, Franco Vera L, Lopez Rodas G, Castillo Aliaga J. Scientific Reports. 2020 Feb 28;10(1):3723. doi: 10.1038/s41598-020-60476-7. PMID: 32111877

Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter «SLAVE» Study. Parisi A, Cortellini A, Cannita K, Venditti O, Camarda F, Calegari M, Salvatore L, Tortora G, Rossini D, Germani M, Boccaccino A, Dell’aquila E, Fulgenzi C, Santini D, Tursi M, Tinari N, Marino P, Lombardi P, Roselló Keränen S, Huerta Alvaro M, Zurlo I, Corsi D, Emiliani A, Zanaletti N, Troiani T, Vitale P, Giampieri R, Merloni F, Occhipinti M, Marchetti P, Roberto M, Mazzuca F, Ghidini M, Indini A, Garajova I, Zoratto F, Monache S, Porzio G, Ficorella C. Cancers. 2020 May 16;12(5):1259. doi: 10.3390/cancers12051259. PMID: 32429380

How we treat metastatic colorectal cancer. De Falco V, Napolitano S, Rosello S, Huerta M, Cervantes A, Ciardiello F, Troiani T. ESMO Open. 2020 Aug;4(Suppl 2):e000813. doi: 10.1136/esmoopen-2020-000813. PMID: 32817137

Impact of perioperative transfusions and sepsis on long-term oncologic outcomes after curative colon cancer resection. A retrospective analysis of a prospective database. Baguena G, Pellino G, Frasson M, Escrig J, Marinello F, Espí Macias A, Garcia-Granero A, Roselló Keränen S, Cervantes Ruiperez A, Garcia-Granero E. Gastroenterologia y Hepatologia. 2020 Feb;43(2):63-72. doi: 10.1016/j.gastrohep.2019.07.005. PMID: 31918857

In the literature: April 2020. Gambardella V, Roda D, Tarazona N, Cervantes A. ESMO Open. 2020 Apr;5(2):e000749. doi: 10.1136/esmoopen-2020-000749. PMID: 32317263

In the literature: August 2020. Gambardella V, Cejalvo J, Tarazona N, Cervantes A. ESMO Open. 2020 Aug;5(4):e000909. doi: 10.1136/esmoopen-2020-000909. PMID: 32817070

In the literature: December 2019. Gambardella V, Insa A, Cejalvo J, Cervantes A. ESMO Open. 2020 Jan;5(1):e000642. doi: 10.1136/esmoopen-2019-000642. PMID: 31958287

In the literature: February 2020. Roda D, Gambardella V, Cejalvo JM, Cervantes A. ESMO Open. 2020 Feb;5(1):e000680. doi: 10.1136/esmoopen-2020-000680. PMID: 32079625

In the literature: June 2020. Roda D, Gambardella V, Cejalvo JM, Cervantes A. ESMO Open. 2020 Jul;5(4):e000832. doi: 10.1136/esmoopen-2020-000832. PMID: 32641355

In the literature: October 2020. Gambardella V, Bruixola Campos G, Alfaro Cervelló C, Cervantes Ruiperez A. ESMO Open. 2020 Oct;5(5):e001048. doi: 10.1136/esmoopen-2020-001048. PMID: 33037034

Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. Guo C, Chenard-Poiriet M, Roda D, de Miguel M, Harris S, Candilejo I, Sriskandarajah P, Xu W, Scaranti M, Constantinidou A, King J, Parmar M, Turner A, Carreira S, Riisnaes R, Finneran L, Hall E, Ishikawa Y, Nakai K, Tunariu N, Basu B, Kaiser M, Lopez J, Minchom A, de Bono J, Banerji U. The Lancet Oncology. 2020 Nov;21(11):1478-1488. doi: 10.1016/S1470-2045(20)30464-2. PMID: 33128873

Intrasinusoidal HHV8-EBV-Positive Large B-Cell Lymphoma With Features of Germinotropic Lymphoproliferative Disorder. Martínez Ciarpaglini M, Valkov A, Hurtado M, Agusti Martinez J, Malave G, Ferrandez Izquierdo A. International Journal of Surgical Pathology. 2020 Oct;28(7):804-811. doi: 10.1177/1066896920921238. PMID: 32423260

JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Yoshino T, Pentheroudakis G, Mishima S, Overman M, Yeh K, Baba E, Naito Y, Calvo F, Saxena A, Chen L, Takeda M, Cervantes Ruiperez A, Taniguchi H, Yoshida K, Kodera Y, Kitagawa Y, Tabernero J, Burris H, Douillard J. Annals of Oncology. 2020 Jul;31(7):861-872. doi: 10.1016/j.annonc.2020.03.299. PMID: 32272210

Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group. Remon J, Nadal E, Domine M, Ruffinelli J, Garcia Y, Pardo JC, Lopez R, Cilleruelo A, Garcia Campelo R, Martin P, Juan O, Gonzalez Larriba JL, Provencio M, Olmedo E, Ponce S, Cumplido D, Barenys C, Majem M, Massutti B, Rodriguez Abreu D, Porta R, Sala MA, Martinez Kareaga M, Lianes P, Reguart N. Lung Cancer. 2020 Sep;147:83-90. doi: 10.1016/j.lungcan.2020.06.034. PMID: 32682189

Managing cancer patients during the COVID-19 pandemic: An ESMO Interdisciplinary Expert Consensus. Curigliano G, Banerjee S, Cervantes Ruiperez A, Garassino M, Garrido P, Girard N, Haanen J, Jordan K, Lordick F, Machiels J, Michielin O, Peters S, Tabernero J, Douillard J, Pentheroudakis G, all Voting Panel members. Annals of Oncology. 2020 Oct;31(10):1320-1335. doi: 10.1016/j.annonc.2020.07.010. PMID: 32745693

Melanoma of Unknown Primary: New Perspectives for an Old Story. Boussios S, Rassy E, Samartzis E, Moschetta M, Sheriff M, Perez-Fidalgo J, Pavlidis N. Critical reviews in oncology/hematology. 2020 Dec 28;158:103208. doi: 10.1016/j.critrevonc.2020.103208. PMID: 33383207

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Provencio M, Nadal E, Insa A, Garcia-Campelo M, Casal-Rubio J, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, Carpeno J, Cobo M, Vivanco G, Del Barco E, Caro R, Vinolas N, Aranda I, Viteri S, Pereira E, Royuela A, Casarrubios M, Anton C, Parra E, Wistuba I, Calvo V, Laza-Briviesca R, Romero A, Massuti B, Cruz-Bermudez A. Lancet Oncology. 2020 Nov;21(11):1413-1422. doi: 10.1016/S1470-2045(20)30453-8. PMID: 32979984

Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer. Papaccio F, Rosello S, Huerta M, Gambardella V, Tarazona N, Fleitas T, Roda D, Cervantes A. Cancers. 2020 Dec 3;12(12):E3611. doi: 10.3390/cancers12123611. PMID: 33287114

Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre. Rosello S, Pizzo C, Huerta M, Munoz E, Aliaga R, Vera A, Alfaro-Cervello C, Jorda E, Garces-Albir M, Roda D, Dorcaratto D, Tarazona N, Torondel S, Guijarro J, Sanchiz V, Gambardella V, Fleitas-Kanonnikoff T, Lluch P, Pascual I, Ferrandez A, Sabater L, Cervantes A. ESMO Open. 2020 Nov;5(6):e000929. doi: 10.1136/esmoopen-2020-000929. PMID: 33229503

New Guidelines for optimal patient care with localized colon cancer: recommending what is proven, but also watching what research is bringing. Tarazona Llavero N, Roda Perez D, Roselló Keränen S, Huerta Alvaro M, Cervantes Ruiperez A. Annals of Oncology. 2020 Oct;31(10):1287-1288. doi: 10.1016/j.annonc.2020.07.012. PMID: 32710931

NOTCH signalling in ovarian cancer angiogénesis. Perez-Fidalgo J, Ortega B, Simon S, Samartzis E, Boussios S. Annals of Translational Medicine. 2020 Dec;8(24):1705. doi: 10.21037/atm-20-4497. PMID: 33490217

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Chen L, Martinelli E, Cheng A, Pentheroudakis G, Qin S, Bhattacharyya G, Ikeda M, Lim H, Ho G, Choo S, Ren Z, Malhotra H, Ueno M, Ryoo B, Kiang T, Tai D, Vogel A, Cervantes Ruiperez A, Lu S, Yen C, Huang Y, Chen S, Hsu C, Shen Y, Tabernero J, Yen Y, Hsu C, Yoshino T, Douillard J. Annals of Oncology. 2020 Mar;31(3):334-351. doi: 10.1016/j.annonc.2019.12.001. PMID: 32067677

Personalized Medicine: Recent Progress in Cancer Therapy. Gambardella V, Tarazona Llavero N, Cejalvo Andujar J, Lombardi P, Huerta Alvaro M, Roselló Keränen S, Fleitas Kanonnikoff T, Roda Perez D, Cervantes Ruiperez A. Cancers. 2020 Apr 19;12(4):1009. doi: 10.3390/cancers12041009. PMID: 32325878

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. Voss MH, Gordon MS, Mita M, Rini B, Makker V, Macarulla T, Smith DC, Cervantes A, Puzanov I, Pili R, Wang D, Jalal S, Pant S, Patel MR, Neuwirth RL, Enke A, Shou Y, Sedarati F, Faller DV, Burris HA. British Journal of Cancer. 2020 Nov;123(11):1590-1598. doi: 10.1038/s41416-020-01041-x. PMID: 32913286

Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers. Yap T, Kristeleit R, Michalarea V, Pettitt S, Lim J, Carreira S, Roda Perez D, Miller R, Riisnaes R, Miranda S, Figueiredo I, Nava Rodrigues D, Ward S, Matthews R, Parmar M, Turner A, Tunariu N, Chopra N, Gevensleben H, Turner N, Ruddle R, Raynaud F, Decordova S, Swales K, Finneran L, Hall E, Rugman P, Lindemann J, Foxley A, Lord C, Banerji U, Plummer R, Basu B, Lopez J, Drew Y, de Bono J.Cancer Discovery. 2020 Oct;10(10):1528-1543. doi: 10.1158/2159-8290.CD-20-0163.PMID: 32532747

Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress. Gambardella V, Fleitas Kanonnikoff T, Tarazona Llavero N, Papaccio F, Huerta Alvaro M, Roselló Keränen S, Gimeno Valiente F, Roda Perez D, Cervantes Ruiperez A. Journal of Clinical Medicine. 2020 Sep 22;9(9):3049. doi: 10.3390/jcm9093049. PMID: 32971757

Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations. Lambertini M, Ameye L, Hamy A, Zingarello A, Poorvu P, Carrasco E, Grinshpun A, Han S, Rousset-Jablonski C, Ferrari A, Paluch-Shimon S, Cortesi L, Senechal C, Miolo G, Pogoda K, Perez Fidalgo J, De Marchis L, Ponzone R, Livraghi L, Estevez-Diz M, Villarreal-Garza C, Dieci M, Clatot F, Berliere M, Graffeo R, Teixeira L, Cordoba O, Sonnenblick A, Luna Pais H, Ignatiadis M, Paesmans M, Partridge A, Caron O, Saule C, Del Mastro L, Peccatori F, Azim H. Journal of Clinical Oncology. 2020 Sep 10;38(26):3012-3023. doi: 10.1200/JCO.19.02399. PMID: 32673153

Sun exposure and PDZK1 genotype modulate PDZK1 gene expression in normal skin. Hernando B, Ibarrola Villava M, Oltra Sanchis S, Valcuende-Cavero F, Pitarch G, Mahiques L, Ribas G, Martinez-Cadenas C. Photodermatology Photoimmunology & Photomedicine. 2020 Jan;36(1):70-72. doi: 10.1111/phpp.12508. PMID: 31444921

Systemic treatment of newly diagnosed advanced epithelial ovarian cancer: From chemotherapy to precision medicine. Perez-Fidalgo J, Grau F, Farinas L, Oaknin A. Critical reviews in oncology/hematology. 2020 Dec 31;158:103209. doi: 10.1016/j.critrevonc.2020.103209. PMID: 33388455

The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper. Valentini V, Marijnen C, Beets G, Bujko K, De Bari B, Cervantes Ruiperez A, Chiloiro G, Coco C, Gambacorta M, Glynne-Jones R, Haustermans K, Meldolesi E, Peters F, Rodel C, Rutten H, van de Velde C, Aristei C. Radiotherapy and Oncology. 2020 Jan;142:6-16. doi: 10.1016/j.radonc.2019.07.001. PMID: 31431374

The actual management of colorectal liver metastases. Pérez Santiago L, Dorcaratto D, Garces Albir M, Muñoz Forner E, Huerta Alvaro M, Roselló Keränen S, Sabater Orti L. Minerva Chirurgica. 2020 Oct;75(5):328-344. doi: 10.23736/S0026-4733.20.08436-9. PMID: 32773753

The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC). Bendell J, Sauri T, Cubillo Gracian A, Alvarez R, Lopez-Lopez C, Garcia-Alfonso P, Hussein M, Limon Miron M, Cervantes Ruiperez A, Montagut C, Santos Vivas C, Bessudo A, Plezia P, Moons V, Andel J, Bennouna J, van der Westhuizen A, Samuel L, Rossomanno S, Boetsch C, Lahr A, Franjkovic I, Heil F, Lechner K, Krieter O, Hurwitz H, McCAVE Study Grp. Oncologist. 2020 Mar;25(3):e451-e459. doi: 10.1634/theoncologist.2019-0291. PMID: 32162804

The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target. Gambardella V, Castillo Aliaga J, Tarazona Llavero N, Gimeno Valiente F, Martínez Ciarpaglini M, Cabeza Segura M, Roselló Keränen S, Roda Perez D, Huerta Alvaro M, Cervantes Ruiperez A, Fleitas Kanonnikoff T. Cancer Treatment Reviews. 2020 Jun;86:102015. doi: 10.1016/j.ctrv.2020.102015. PMID: 32248000

Trifluridine/Tipiracil in earlier lines of chemotherapy for advanced colorectal cancer. Roda Perez D, Roselló Keränen S, Huerta Alvaro M, Cervantes Ruiperez A. Annals of Oncology. 2020 Sep;31(9):1097-1098. doi: 10.1016/j.annonc.2020.05.030. PMID: 32544547